- North Carolina system invests $200M in cancer care
- UnityPoint Health to transition dental services to FQHC
- 10 trends in behavioral health usage: Report
- How hospitals are winning — and losing — the ASC moment
- 4 DSOs adding new technology
- Hawaii system names interim CEO
- Aspen Dental opens Michigan office
- Turning fragmented clinical data into actionable insight
- Ascension taps president for 2 Texas hospitals
- Colorado hospital saves money by dual training clinicians as interpreters
- Walmart expands GLP-1 care, pharmacy integration
- Mississippi hospital files for bankruptcy
- Studies reaffirm fluoride safety, benefits: 10 things to know
- Philips earns FDA clearance for spectral CT with cardiac imaging
- Pennsylvania hospital shifts to outpatient-focused model
- New Oklahoma law closes dental insurer price fixing loophole
- Cattywampus: Statement on the CAT Concept Release
- Nicklaus Children’s performs Florida’s 1st partial heart transplant
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Why tech, workforce are key to Prisma outpatient pharmacy growth
- The ASC block time problem
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- How HCA, Tenet and CHS’ hospital portfolios shifted in 2025
- Agentic AI arrives for nursing shifts and health system call centers
- Investment firm acquires 2 Maryland medical office buildings
- The ‘Darwinian’ evolution of independent physicians
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- Air Pollution and Weather Tied to Migraines
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- Kentucky approves changes to Dental Practice Act
- Physicians’ greatest ASC pain point
- The highest-paid gastroenterologist in the 10 largest Western cities
- WVU Medicine to build $25M MOB
- Former Utah dentist accused of practicing dentistry without a license
- 7 dental companies gaining new funding
- Heartland Dental adds Michigan practice
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- Where dental therapy stands in the U.S.
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- EPA Delays Decisions on 'Forever Chemicals'
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- ‘Mini specialists’: 5 models reshaping behavioral health in primary care
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- Progyny unveils new fertility benefit option for small, mid-size employers
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Medi-Cal Immigrant Enrollment Is Dropping. Researchers Point to Trump’s Policies.
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Chicago hospital expands outpatient, walk-in mental health services
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- Hospitals with more disadvantaged patients fall short on price transparency, study finds
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Bill would force payers to apply DTC drug purchases to patient deductibles
- 43 states have mental health insurance disparities: 4 trends
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- The new playbook for clinician well-being
- Listen to the Latest ‘KFF Health News Minute’
- Estados cambian leyes para evitar que hijos de inmigrantes detenidos entren al sistema de cuidado temporal
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- Cómo hacer que un plan de salud con deducible alto funcione para tí
- Anthem, Mount Sinai reach contract agreement, restore in-network coverage
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Stanford Health Care, Alameda Health System partner to support St. Rose Hospital
- Para muchos pacientes que salen de terapia intensiva, la lucha apenas comienza
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- Does Your Child Have Nightmares? Here's One Solution
- Marriage's Hidden Benefit? A Lower Risk Of Cancer
- Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
- Los estados se enfrentan a otro reto con las nuevas reglas laborales de Medicaid: la falta de personal
- States Change Custody Laws To Keep Children of Detained Immigrants Out of Foster Care
- WebMD Ignite rolls out program to help providers get Rural Health Transformation efforts off the ground
- Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
- NewYork-Presbyterian to enact behavioral health reforms, pay $500K in wake of investigation
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- California behavioral health hospital to add inpatient beds
- Freedom of Associations
- Pioneering exposure therapy psychologist dies
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- New Mental Health Parity Index highlights where disparities persist
- CMS taps 150 digital health companies, providers for ACCESS Model
- Optum allows mental health NPs to offer transcranial magnetic stimulation
- Wavelet Medical, Aegis Ventures partner on first AI non-invasive fetal EEG monitoring platform
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- New Rules May Allow Broader Picks for CDC Vaccine Panel
- Second Meningitis Vaccine Doses Offered After U.K. Outbreak
- Crackdown on Vapes Falling Short, Report Finds
- Jasmine Rice Recalled Nationwide Over Possible Contamination
- ‘The next opioid epidemic’: Gambling legalization outpaces public health response to addiction
- Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare
- Fighting High Blood Pressure? Having A Team On Your Side Can Help
- Radon Gas Increases Risk Of Ovarian Cancer, Study Says
- Your Doctor Might Be Using The Wrong Test To Track Your Cholesterol, Study Says
- Losing Teeth May Lead to Weight Gain, Researchers Report
- Heart Risk Worse With Sleep Apnea That Varies Night-By-Night
- Lilly’s Jaypirca shows fixed-duration power in ‘ambitious’ phase 3 CLL trial win
- ViiV launches ‘Still Here’ campaign aimed at reminding young people about HIV
- Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
- How to Limit The Health Risks Posed by Polluted Air
- U.S. States Warm, But Not As Expected
- HHS, after legal setback, updates ACIP charter to put more emphasis on vaccine safety
- Costco Recalls Cookies Over Missing Nut Allergy Warning
- CDC Pauses Release of COVID Vaccine Effectiveness Study
- Statement Regarding Staff No-Action Letter to Bank of England
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
- Blackstone and TPG Complete Acquisition of Hologic; Names New CEO
I have promoted OTC status for Ivermectin since early 2022, when I pointed out that raging social media warriors were wrong to demand hospitals include it in protocols. The large meta-study available at the time did not include data from late (hospital) treatment. However, it did demonstrate that
... early treatment allowed most to avoid the hospital entirely.
In addition to early treatment success, people know their own symptoms and results best. When an endemic disease has safe treatment, it’s common sense to self-treat and avoid hospitals.
MedPage Today reviews states doing just that.
https://www.medpagetoday.com/special-reports/features/116436
These States Now Allow OTC Ivermectin, and More May Follow
— Four have passed new laws, and at least nine have legislation in the works
by Rachael Robertson | July 9, 2025
A handful of states have passed legislation allowing ivermectin to be sold and purchased over-the-counter (OTC) -- and other state legislatures have their sights set on doing the same.
During the pandemic, rampant misinformation drew attention to the antiparasitic as a treatment for COVID, though research continues to show it is not effective against the disease.
Ivermectin tablets are FDA approved at specific doses for treating some parasitic worms, as are topical formulations for some skin conditions and head lice, but neither are FDA approved for preventing or treating COVID. Despite this, an increasing number of states are making it easier to get ivermectin and protecting pharmacists from lawsuits and discipline by licensing boards. None of the laws have information about dosing.
Currently four states -- Tennessee, Arkansas, Idaho, and Louisiana -- have passed OTC ivermectin laws.
In April 2022, Tennessee passed SB 2188/HB 2746, becoming the first state to make ivermectin available OTC. The legislation authorizes "ivermectin suitable for human use" to be sold or purchased OTC "without a prescription or consultation with a pharmacist or other healthcare professional." For 3 years, Tennessee was the only state to have OTC ivermectin.
Then on March 25 of this year, Arkansas passed SB 189, now Act 396. Weeks later, on April 14, Idaho passed similar OTC ivermectin legislation, SB 1211.
Louisiana SB 19, now Act 464, went into effect on June 20, making it the latest state to make ivermectin available OTC. This law specifies that a pharmacist can dispense ivermectin to adults "pursuant to a standing order issued by a healthcare professional with prescriptive authority" and requires the pharmacist to provide the patient with information on indications and contraindications as well as a screening risk assessment tool. For this service, the pharmacy may charge an administrative fee. Ralph Abraham, MD, the state's surgeon general, backed the bill.
In addition to these, other states have bills moving through their legislatures:
Texas
Just this week, 20 Texas House Republicans asked Gov. Greg Abbott (R) to add the reclassification of ivermectin as OTC -- under proposed HB 3219 -- to the agenda for a special session set to begin later this month. Some of these lawmakers have connected the issue to medical freedom.
New Hampshire
A bill with a unique two-fold approach, SB 119, was introduced in May, which lumps together ivermectin access with an unrelated Medicaid provision. The bill would allow pharmacists to follow a standing order from a physician, physician assistant, or advance practice registered nurse to dispense ivermectin alongside an information sheet on side effects. Also included are various protections against disciplinary action for these healthcare professionals.
The paired Medicaid provision "directs pharmacists to dispense brand name drugs to Medicaid beneficiaries when the brand name drug is on the department of health and human services preferred drug list."
North Carolina
The Ivermectin Access Act, or HB 618, was proposed in April 2025. This legislation would direct the state health director "to issue a statewide standing order to allow pharmacists to dispense ivermectin without prescription" as well as "providing immunity from civil or criminal liability" for both the director and any pharmacist who dispenses ivermectin.
Pennsylvania
Also in April, a lawmaker proposed SB 601, which would amend the state's Pharmacy Act to make ivermectin available OTC.
Georgia
In March, SB 366 was first proposed to amend parts of the Official Code of Georgia Annotated related to controlled substances and to pharmacists and pharmacies. This would "provide for ivermectin as an over-the-counter medication in this state" and "remove ivermectin from the definition of, exceptions to, and exemptions from dangerous drugs."
Alabama
A lawmaker brought forth HB 278 in February, which would "permit a physician, a physician assistant, or a certified registered nurse practitioner to give a pharmacist a standing order that has been approved by the State Board of Pharmacy to dispense ivermectin to individuals without a prescription." The standing order would involve a risk assessment protocol and a standardized information sheet.
It also has various disciplinary protections for pharmacists and forbids them from participating in "any program or accept anything of value that induces the healthcare provider or pharmacist to affirmatively commend or endorse the use of ivermectin to an individual or the public."
If passed, the legislation would take effect in October of this year.
West Virginia
SB 614 was also introduced in February. The bill would authorize pharmacists to dispense ivermectin without a prescription or consultation and protect them from liability from damages or licensing board discipline.
Missouri
SB 744, which would make both ivermectin and hydroxychloroquine available OTC, was introduced in February, though it has not made much progress. A similar bill, HB 2581, was proposed in January 2024, but never passed.
South Carolina
HB 3916, proposed in February, also aims to make both ivermectin and hydroxychloroquine available without prescription or consultation.
Axios's Ivermectin update couldn't be more biased, but hang in there: the good stuff is toward the end.
https://www.axios.com/local/phoenix/2026/02/02/ivermectin-over-the-counter-arizona-bill
Arizona bill would let people buy ivermectin without a prescription
Jessica Boehm, Kim Bojórquez | Feb. 2, 2026
Republicans in Arizona and nationwide are trying to make it easier to get ivermectin, the controversial anti-parasitic drug widely used to treat livestock but embraced by some as a treatment during the pandemic.
Why it matters: Ivermectin was promoted largely by conservatives as a "miracle" drug amid the COVID-19 pandemic, despite multiple medical studies that found it isn't effective at treating the novel coronavirus, and repeated warnings from leading medical institutions outside of FDA-approved use. Still, it has persisted as an alternative treatment for COVID.
The drug is approved for human use to treat parasitic worms and conditions such as head lice and rosacea, per the FDA.
State of play: Arizona State Rep. Nick Kupper (R- Surprise) sponsored a bill to make ivermectin that's formulated for human use available over the counter without a prescription or medical consultation.
The measure has not yet been scheduled for a hearing.
The intrigue: Kupper, who did not respond to Axios' interview request, told Arizona's Family he introduced the bill in response to constituent interest in the drug, and he dismissed health concerns.
"Think about how many energy drinks we drink every day. There's caffeine in coffee or vaping or smoking cigarettes. … These are all things that you don't need a prescription to get," Kupper told Arizona's Family.
The other side: Doctors and toxicologists, including the American Medical Association, American Pharmacists Association and American Society of Health-System Pharmacists, have widely cautioned against ivermectin use.
During the pandemic, the Banner Poison and Drug Information Center in Phoenix and Arizona Poison and Drug Information Center in Tucson said they received several calls concerning ivermectin exposure.
"Higher doses can cause significant illness in humans," Daniel Brooks, then the medical director of the Banner Poison and Drug Information Center, said in a 2021 statement.
Reality check: Will Humble, executive director for the Arizona Public Health Association, told Axios the bill is "performative."If it reaches Democratic Gov. Katie Hobbs' desk, she'll almost certainly veto it, he said.
Even so, it's unlikely that national chain pharmacies would stock the drug — even if given state approval — because of federal legal and licensure risks.Plus, people who really want ivermectin can already get it at many of Arizona's livestock supply stores without a prescription, because it's widely used for deworming horses.
Zoom out: At least five states have already legalized ivermectin sales without a prescription: Texas, Tennessee, Arkansas, Idaho and Louisiana.Republican Utah state Rep. Trevor Lee introduced a bill in his state, telling Axios it would expand medical freedom and align with Health and Human Services Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















